Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab

NCT00137995 is registered in ClinicalTrials.gov with Lymphoma Study Association as lead sponsor.

NCT NCT00137995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00137995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab
Lead sponsor
Lymphoma Study Association
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2003
Completion date
October 31, 2008
Enrollment
481 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, large-cell, diffuse